Clinical Trial Update: A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating all-cause hospitalizations for Abilify MyCite users versus virtual matched controls in adults with schizophrenia, bipolar I disorder, a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Major Depressive Disorder
• Schizophrenia

Drugs mentioned

• Abilify MyCite (aripiprazole)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Schizophrenia, Bipolar 1 Disorder | Phase 4 | Status: TERMINATED | Results posted: 2019-11-08